Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7


Monocyte activation from interferon-α in HIV infection increases acetylated LDL uptake and ROS production.

Pulliam L, Calosing C, Sun B, Grunfeld C, Rempel H.

J Interferon Cytokine Res. 2014 Oct;34(10):822-8. doi: 10.1089/jir.2013.0152. Epub 2014 Apr 14.


HIV-1 Nef impairs key functional activities in human macrophages through CD36 downregulation.

Olivetta E, Tirelli V, Chiozzini C, Scazzocchio B, Romano I, Arenaccio C, Sanchez M.

PLoS One. 2014 Apr 4;9(4):e93699. doi: 10.1371/journal.pone.0093699. eCollection 2014.


Dendritic cells/natural killer cross-talk: a novel target for human immunodeficiency virus type-1 protease inhibitors.

Giardino Torchia ML, Ciaglia E, Masci AM, Vitiello L, Fogli M, la Sala A, Mavilio D, Racioppi L.

PLoS One. 2010 Jun 10;5(6):e11052. doi: 10.1371/journal.pone.0011052.


A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy.

Raboud JM, Diong C, Carr A, Grinspoon S, Mulligan K, Sutinen J, Rozenbaum W, Cavalcanti RB, Wand H, Costagliola D, Walmsley S; Glitazone and Lipoatrophy Meta-Analysis Working Group.

HIV Clin Trials. 2010 Jan-Feb;11(1):39-50. doi: 10.1310/hct1101-39.


HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by reducing CD36 and CPT1 fatty acid transporters.

Richmond SR, Carper MJ, Lei X, Zhang S, Yarasheski KE, Ramanadham S.

Biochim Biophys Acta. 2010 May;1801(5):559-66. doi: 10.1016/j.bbalip.2010.01.007. Epub 2010 Feb 1.


CD36: implications in cardiovascular disease.

Febbraio M, Silverstein RL.

Int J Biochem Cell Biol. 2007;39(11):2012-30. Epub 2007 Mar 23. Review.


HIV protease inhibitors and atherosclerosis.

Hui DY.

J Clin Invest. 2003 Feb;111(3):317-8. Review. No abstract available.

Supplemental Content

Support Center